** Brokerage Jefferies raises PT on drug developer Xenon Pharmaceuticals XENE.O to $65 from $60; maintains "buy" rating
** New PT represents a 62% upside to the stock's last close
** Brokerage says it sees a "catalyst-rich period" ahead for XENE, driven by multiple late-stage trials of co's experimental drug XEN1101 targeting epilepsy and depression
** Brokerage says XENE is on track to report data from the first of its two ongoing late-stage trials of XEN1101 in H2 this year, which could result in a "15-35% stock move"
** Brokerage places probability of success at between 80% and potentially higher than 85% for the trial
** XENE fell 12.7% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.